Search results for "chronic"

showing 10 items of 3309 documents

Peripheral nerve involvement in chronic liver disease. Clinical and electrophysiological study.

1986

A clinical and electrophysiological study was carried out on 19 selected patients with chronic liver disease. Clinical signs of peripheral nerve involvement were found in 4 patients (21%); while electrophysiological impairment was present in 11 patients (57.8%). These abnormalities were mostly limited to the sensory and motor fibers of the tibialis posterior nerve. Our data confirm the presence of peripheral nerve involvement in chronic liver disease, and that it may be evidenced by careful electrophysiological examination.

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyNeurologyNeural ConductionSensory systemDermatologyChronic liver diseasePeripheral nervemedicineHumansNeuroradiologyAgedHepatitis Chronicbusiness.industryGeneral NeuroscienceLiver DiseasesPeripheral Nervous System DiseasesGeneral MedicineMiddle Agedmedicine.diseasePsychiatry and Mental healthElectrophysiologyToxic neuropathyChronic DiseaseFemaleNeurology (clinical)NeurosurgerybusinessItalian journal of neurological sciences
researchProduct

Ultrasound detection of abdominal lymph nodes in chronic liver diseases. A retrospective analysis

2003

Aim: To retrospectively evaluate the prevalence of lymph nodes of the hepato-duodenal ligament in a group of patients with chronic liver disease of various aetiologies and to investigate what clinical, aetiological and laboratory data may lead to their appearance. Materials and methods: One thousand and three patients (554 men, 449 women) were studied, including 557 with chronic hepatitis and 446 with liver cirrhosis. The presence of lymph nodes near the trunk of the portal vein, hepatic artery, celiac axis, superior mesenteric vein and pancreas head was investigated using ultrasound. Results: Lymph nodes were detected in 394 out of the 1003 study patients (39.3%); their number ranged from …

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyRadiology Nuclear Medicine and ImagingCirrhosisAbdominal lymph nodeAutoimmune hepatitisAutoimmune hepatitiChronic liver diseaseGastroenterologyHepatitisLiver diseasePrimary biliary cirrhosisLiver Function TestsInternal medicineAbdomenUltrasoundmedicineHumansLiver Diseases AlcoholicLymphatic DiseasesLymph nodeAgedRetrospective StudiesUltrasonographyHepatitisbusiness.industryLiver DiseasesChronic liver diseaseGeneral MedicineMiddle Agedmedicine.diseasemedicine.anatomical_structureOncologyChronic DiseaseFemaleHemochromatosisLymph NodesLymphbusiness
researchProduct

Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease

2001

BACKGROUND—It has been suggested that serological screening for coeliac disease (CD) should be performed in patients with chronic unexplained hypertransaminasaemia.
AIMS—To evaluate the specificity for CD diagnosis of serum IgA antitissue transglutaminase (tTG) determination in consecutive patients with chronic hypertransaminasaemia using the most widely utilised ELISA based on tTG from guinea pig as the antigen.
PATIENTS AND METHODS—We studied 98 patients with chronic hypertransaminasaemia, evaluated for the first time in a hepatology clinic. Serum anti-tTG and antiendomysial (EmA) assays were performed. Patients positive for EmA and/or anti-tTG were proposed for intestinal biopsy. Finally…

AdultLiver CirrhosisMalemedicine.medical_specialtySettore MED/09 - Medicina InternaCirrhosisAdolescentHepatitis Viral HumanTissue transglutaminaseGuinea PigsAutoimmunityEnzyme-Linked Immunosorbent AssayChronic liver diseaseSensitivity and SpecificityCoeliac diseaseArticleStatistics NonparametricAntiendomysial antibodieIntestinal histologySerologyLiver diseaseIntestinal mucosaPredictive Value of TestsInternal medicinemedicineAnimalsHumansFalse Positive ReactionsTransaminasesAutoantibodiesTransglutaminasesCoeliac diseasebiologybusiness.industryAntitissue transglutaminase antibodieGastroenterologyHepatologyMiddle Agedmedicine.diseaseImmunoglobulin ACeliac DiseaseImmunologyChronic Diseasebiology.proteinLinear ModelsFemalebusinessLiver disease
researchProduct

Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population.

2016

Background & Aims: Life expectancy of patients with compensated hepatitis C virus (HCV) cirrhosis achieving sustained virologic response (SVR) is limited by liver events as compared to the general population. Thus, survival benefit of SVR remains to be measured. Methods: The study includes prospective surveillance data from three cohorts of Italian patients with compensated HCV cirrhosis who achieved SVR on an interferon-based (IFN) regimen, compared to simultaneously observed non-SVR, untreated and decompensated patients. Overall survival was calculated from the date of start of IFN to death. The number of deaths expected during the at-risk period was determined by applying age- and se…

AdultLiver CirrhosisMalemedicine.medical_specialtySustained Virologic ResponsePopulation03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansProspective StudieseducationSurvival analysisAgededucation.field_of_studyHepatologybusiness.industryMortality rateHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseSurgerySurvival RateRegimenStandardized mortality ratio030220 oncology & carcinogenesisRelative riskHCVFemale030211 gastroenterology & hepatologyInterferonsViral hepatitisbusiness
researchProduct

Predicting Mortality Risk in Patients With Compensated HCV-Induced Cirrhosis: A Long-Term Prospective Study

2009

OBJECTIVES: The identification of prognostic factors associated with mortality is crucial in any clinical setting. METHODS: We enrolled in a prospective study 352 patients with compensated hepatitis C virus (HCV)-induced cirrhosis, consecutively observed between 1989 and 1992. At entry, patients underwent upper endoscopy to detect esophageal varices, and were then surveilled by serial clinical and ultrasonographic examination. The model for end-stage liver disease (MELD) score was calculated with information collected at enrollment. Baseline predictors and intercurrent events associated with mortality were assessed using the Cox regression model. RESULTS: During a median follow-up of 14.4 y…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsCirrhosisBiopsy Fine-NeedleKaplan-Meier EstimateEsophageal and Gastric VaricesAntiviral AgentsRisk AssessmentSeverity of Illness IndexGastroenterologyCohort StudiesPredictive Value of TestsCause of DeathInternal medicineEpidemiologyConfidence IntervalsmedicineHumansProspective StudiesRisk factorProspective cohort studyAgedProbabilityProportional Hazards ModelsCause of deathSettore MED/12 - GastroenterologiaHepatologybusiness.industryGastroenterologyInterferon-alphavirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseImmunohistochemistrySurvival Analysisliver cirrhosis natural historyDisease ProgressionFemalebusinessRisk assessmentLiver FailureFollow-Up StudiesCohort studyThe American Journal of Gastroenterology
researchProduct

Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study

2019

Abstract Background Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients. In this study we aimed to assess predictors of mortality in one of the largest CHB cohorts in sub-Saharan Africa. Methods Two-hundred-and-seventy-six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia between March 18, 2015, and August 1, 2017, were included in this analysis. Patients were followed up until October 1, 2017, and deaths were ascertained through hospital records and telephone interview with relatives. Decompensated cir…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsSurvivalAdolescentEpidemiologyPhysical examinationAntiviral therapyAntiviral AgentsBody Mass Index03 medical and health sciencesYoung Adult0302 clinical medicineHepatitis B ChronicInterquartile rangeRisk FactorsInternal medicineEpidemiologyMedicineHumansProspective Studieslcsh:RC799-869Prospective cohort studyTenofovirProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryHazard ratioGastroenterologyAge FactorsGeneral MedicineHepatitis BHepatologyMiddle Agedmedicine.diseaseHepatitis BResource-limited settingsSurvival RateVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesislcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyFemaleEthiopiabusinessBody mass indexResearch Article
researchProduct

Hepatitis C virus-specific T-cell-derived transforming growth factor beta is associated with slow hepatic fibrogenesis.

2011

Up to 4 million persons in the USA have chronic hepatitis C (CHC) (1). Despite a decline in overall HCV infections, the number of patients with end stage liver disease due to CHC will increase for the next 2 decades (2). Even with highly effective novel therapies, currently 30–50% of infected individuals fail treatment (3). Therefore, a better understanding of mechanisms involved in CHC-related liver disease progression could permit more efficient therapies. Adaptive effector T cells (frequently assessed by measuring production of prototypic T helper 1 cytokine IFNγ) play an important role in control of HCV infection during the acute phase (4). In CHC, effector HCV-specific T cell immune re…

AdultLiver CirrhosisMalemedicine.medical_treatmentT cellGene ExpressionHepacivirusBiologyCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryCollagen Type IArticleInterferon-gammaImmune systemTransforming Growth Factor betamedicineHepatic Stellate CellsCytotoxic T cellHumansIL-2 receptorAgedHepatologyViral Core ProteinsFOXP3Hepatitis C ChronicMiddle AgedInterleukin-10Collagen Type I alpha 1 ChainInterleukin 10Cytokinemedicine.anatomical_structureCross-Sectional StudiesLiverImmunologyDisease ProgressionFemaleMatrix Metalloproteinase 1CD8Hepatology (Baltimore, Md.)
researchProduct

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus …

2012

Background. Polymorphisms in the interleukin-28B are important determinants in the spontaneous and drug-induced control of hepatitis C virus infection. Design and Methods. We assessed the association of rs8099917 and rs12979860 polymorphisms with spontaneous viral clearance, severity of liver fibrosis, and response to interferon-monotherapy in 245 Thalassemia Major patients with Hepatitis C Virus infection. Results. Ninety-eight patients (40%) had a spontaneous viral clearance, while 147 patients (60%) developed a chronic infection. Spontaneous viral clearance was more frequent among patients with the T/T genotype of rs8099917 polymorphism (OR 2.130; p=0.008) or C/C genotype of rs12979860 p…

AdultLiver CirrhosisMalethlassemia hepatitis CInterferon InducersAdolescentHepacivirusHepatitis C virusAlpha interferonHepacivirusAdolescent; Adult; Antibodies Viral; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Chronic; Humans; Interferon Inducers; Interferon-alpha; Interleukins; Liver Cirrhosis; Male; Polymorphism Single Nucleotide; Prognosis; Viral Load; Young Adult; beta-Thalassemiamedicine.disease_causeAntibodies ViralAntiviral AgentsPolymorphism Single NucleotideCohort StudiesYoung AdultGenotypemedicineHumansInterferon inducerbiologymedicine.diagnostic_testInterleukinsbeta-ThalassemiaInterferon-alphaHematologyHepatitis CHepatitis C ChronicViral Loadbiology.organism_classificationmedicine.diseasePrognosisLiver biopsyImmunologyFemaleInterferonsOriginal Articles and Brief ReportsViral loadFollow-Up Studies
researchProduct

What proportion of chronic obstructive pulmonary disease outpatients is eligible for inclusion in randomized clinical trials?

2013

<b><i>Background and Objective:</i></b> We aimed to explore to what extent an unselected population of chronic obstructive pulmonary disease (COPD) outpatients would be eligible for inclusion in randomized clinical trials (RCTs). <b><i>Methods:</i></b> Retrospective analysis of the clinical records of outpatient subjects with an ascertained diagnosis of COPD. COPD outpatients were assessed against the following inclusion criteria: 40 < age < 80 years, current or former smokers, forced expiratory volume in the first second (FEV<sub>1</sub>) <70% predicted, no long-term oxygen therapy, no other concomitant lung diseases and …

AdultLung DiseasesMalePulmonary and Respiratory Medicinemedicine.medical_specialtyMEDLINEPulmonary diseaseComorbiditySettore MED/10 - Malattie Dell'Apparato Respiratoriolaw.inventionCohort StudiesPulmonary Disease Chronic ObstructiveRandomized controlled triallawForced Expiratory VolumeInternal medicinePragmatic Clinical Trials as TopicmedicineHumansCOPDAgedRandomized Controlled Trials as TopicRetrospective StudiesAged 80 and overCOPDbusiness.industryPatient SelectionSmokingAge FactorsOxygen Inhalation TherapyRetrospective cohort studyMiddle Agedmedicine.diseaseComorbidityBronchiectasisrespiratory tract diseasesPhysical therapyFemaleObservational studyCognition DisordersbusinessCohort study
researchProduct

Spontaneous Monokine Release by Alveolar Macrophages in Chronic Sarcoidosis

1991

In pulmonary sarcoidosis an activation of alveolar T lymphocytes and alveolar macrophages (AM) has been demonstrated. There is evidence that in contrast to acute disease a heightened T-cell response cannot be observed in the chronic phase of sarcoidosis. The role of AM in the inflammatory process of chronic sarcoidosis is not yet intensively evaluated. To address this question we measured the release of tumor necrosis factor alpha (TNFα) and interleukin-1 (IL-1) by AM of 39 patients with chronic sarcoidosis (duration > 4 years; 30 active, 9 inactive diseases) without therapy and correlated the monokine release with parameters of T-cell alveolitis and the course of the disease. The T4/T8 …

AdultLung DiseasesMaleSarcoidosisT-Lymphocytesmedicine.medical_treatmentImmunologyCD4-CD8 Ratio610 MedizinBronchoalveolar Lavage Fluid/immunologyTumor Necrosis Factor-alpha/biosynthesisLymphocyte Activation/immunologyLymphocyte ActivationMacrophages AlveolarmedicineHumansImmunology and AllergyMacrophageAntibodies Monoclonal/immunologyInterleukin-1/biosynthesisddc:610Tumor Necrosis Factor-alphabusiness.industryRespiratory diseaseAntibodies MonoclonalInterleukinGeneral MedicineT-Lymphocytes/immunologymedicine.diseaseSarcoidosis/immunologyMonokineLung Diseases/immunologyCytokinemedicine.anatomical_structureChronic DiseaseImmunologyMacrophages Alveolar/immunologyFemaleTumor necrosis factor alphaSarcoidosisPulmonary alveolusbusinessBronchoalveolar Lavage FluidInterleukin-1International Archives of Allergy and Immunology
researchProduct